Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-Study Group (AGO-GYN8).
Gynecologic Oncology（2016）
摘要
•Temsirolimus has marginal activity in ovarian and endometrial cancer•Durable disease stabilisation was observed in some patients•Toxicity was acceptable
更多查看译文
关键词
Ovarian cancer,Endometrial cancer,Temsirolimus,mTOR inhibitor,Rapalog
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要